公开(公告)号：US20220072045A1

公开(公告)日：2022-03-10

申请号：US17525802

申请日：2021-11-12

申请人： NantCell ,  Nant Holdings IP, LLC

发明人： Shahrooz Rabizadeh ,  Kayvan Niazi ,  Patrick Soon-Shiong ,  Hing Wong ,  Wenxin Xu

IPC分类号： A61K35/17 ,  A61K31/675 ,  C07K14/52 ,  C12N15/86

摘要： Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

公开(公告)号：US11229668B2

公开(公告)日：2022-01-25

申请号：US16483978

申请日：2018-02-08

申请人： NANTCELL, INC. ,  NANT HOLDINGS IP, LLC

发明人： Shahrooz Rabizadeh ,  Kayvan Niazi ,  Patrick Soon-Shiong ,  Hing Wong ,  Wenxin Xu

IPC分类号： A61K35/17 ,  A61K31/675 ,  C07K14/52 ,  C12N15/86

摘要： Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.